Completed OBSERVATIONAL NCT01285167

Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA) (DACOTA)

Daxas for COPD Therapy (DACOTA)

Sponsor: AstraZeneca

Conditions Chronic Obstructive Pulmonary Disease

Interventions Daxas

Updated 8 times since 2017 Last updated: Oct 27, 2016 Started: Aug 31, 2010 Primary completion: Feb 29, 2012 Completion: Feb 29, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Chronic Obstructive Pulmonary Disease and is currently completed. AstraZeneca leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed
Sep 2025 — Jan 2026 [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahlen, Germany , Allendorf, Germany , Allersberg, Germany , Alpenrod, Germany , Altena, Germany , Altenburg, Germany , Alzenau in Unterfranken, Germany , Alzey, Germany , Amberg, Germany , Anklam, Germany and 437 more locations